(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Verve Therapeutics stock jumped after a report said pharmaceutical giant Eli Lilly is in advanced talks to buy the ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Analysts are raising their ratings and price targets on Verve Therapeutics stock today. Verve published very encouraging trial data for its VERVE-102 treatment yesterday. Investors think that the ...

Investors might want to bet on Verve Therapeutics (VERV), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Verve Therapeutics is at the forefront of a new wave of gene editing therapies aimed at tackling cardiovascular diseases, which remain a leading cause of death worldwide. The company’s primary ...

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.